Cardio Diagnostics Receives Final Medicare Pricing Determination for AI-Powered Tests

Cardio Diagnostics Holdings, an AI-driven cardiovascular medicine company, has received final Medicare pricing determinations for its PrecisionCHD and Epi+Gen CHD tests from the Centers for Medicare & Medicaid Services. The CMS finalized the 'gapfill' pricing determination, allowing Medicare contractors to determine pricing based on actual cost data from January 1, 2025. This marks a key milestone in gaining broad access to Medicare reimbursement.

Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), a pioneering AI-driven precision cardiovascular medicine company, recently announced that it has received final pricing determinations from the Centers for Medicare & Medicaid Services (CMS) for its PrecisionCHD and Epi+Gen CHD tests [1]. This significant milestone brings Cardio Diagnostics one step closer to securing Medicare reimbursement, expanding access to its innovative and scalable blood tests designed to improve risk assessment, diagnosis, management, and monitoring of coronary heart disease (CHD) for Medicare patients.

The CMS finalized the 'gapfill' pricing determination, enabling Medicare contractors to determine pricing based on actual cost data from January 1, 2025 [1]. This decision recognizes the unique value of these tests, following the Clinical Laboratory Fee Schedule (CLFS) Annual Public Meeting held on June 25, 2024. If finalized, this decision will be effective for claims with dates of service on or after January 1, 2025 [1].

Cardiovascular disease is the leading cause of death in the United States, with 702,880 deaths in 2022, a mortality rate of 211 deaths per 100,000 population [1]. Coronary heart disease, the most common type of heart disease, claimed 371,506 lives that year [1]. PrecisionCHD, an AI-powered blood test, aids in the diagnosis of CHD by evaluating genetic and epigenetic markers [1]. Epi+Gen CHD assesses the three-year risk for a CHD event, including heart attacks, using a similar AI-driven integrated genetic-epigenetic approach [1].

Cardio Diagnostics' CEO and Co-Founder, Meesha Dogan, Ph.D., expressed her pride in reaching this crucial milestone with CMS, stating, "This determination underscores the value of innovation in healthcare, and we're excited to support clinicians with advanced tools that can enhance the diagnosis and management of coronary heart disease, ultimately improving outcomes for one of the most at-risk populations" [1].

References:
[1] Cardio Diagnostics Holdings, Inc. (2023, March 21). Cardio Diagnostics Holdings, Inc. Receives Final Medicare Pricing Determinations for AI-Powered Cardiovascular Tests. Retrieved March 24, 2023, from https://cdio.ai/cardio-diagnostics-holdings-inc-receives-final-medicare-pricing-from-centers-for-medicare-and-medicaid-services-cms-for-ai-powered-cardiovascular-tests/